Rising Neurodegenerative Disorders Drive Growth In HDAC Inhibitors Market: Pivotal Factor Influencing Histone Deacetylase (HDAC) Inhibitors Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Histone Deacetylase (HDAC) Inhibitors Market Size Growth Forecast: What to Expect by 2025?
The market for histone deacetylase (HDAC) inhibitors has seen substantial growth in the last few years. The market is predicted to expand from a size of $1.23 billion in 2024 to $1.33 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The surge during the historical period can be linked to upsurge in funds for research in epigenetics, a rising occurrence of drug-resistant cancers, increased healthcare spending, the growing use of HDAC inhibitors in animal medicine, and a rise in investments in the field of bioinformatics.

How Will the Histone Deacetylase (HDAC) Inhibitors Market Size Evolve and Grow by 2029?
The size of the market for inhibitors of histone deacetylase (HDAC) is predicted to witness robust growth in the forthcoming years, ballooning to $1.77 billion by the year 2029, with a compound annual growth rate (CAGR) of 7.5%. Factors propelling this surge during the forecast period include the escalating incidence of neurodegenerative disorders, heightened awareness about cancer, increased funding for drug research, a rising number of clinical trials, and a greater acceptance of personalized medicine. Key trends for the forecast period encompass technological progress, tailored medicine, synergies in cancer immunotherapy, the incorporation of digital health solutions, and bioinformatics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report

What Drivers Are Propelling the Growth of Histone Deacetylase (HDAC) Inhibitors Market Forward?
The increasing prevalence of neurodegenerative diseases is anticipated to boost the expansion of the histone deacetylase (HDAC) inhibitors market in the future. These diseases, which involve the gradual decay and eventual loss of neurons in the brain and spinal cord, result in cognitive and motor dysfunction and comprise conditions like Alzheimer's, characterized by memory loss and cognitive decline caused by amyloid plaques and tau tangles. The escalating prevalence of neurodegenerative conditions can be traced back to factors such as advanced age, long lifespan, genetic influence, and environmental elements. Histone deacetylase (HDAC) inhibitors are being researched as potential therapeutic approaches for neurodegenerative diseases due to their capacity to regulate gene expression and produce neuroprotective impacts. For example, the Centers for Disease Control and Prevention, a federal agency in the United States, reported in August 2024 that about 6.7 million senior citizens in the US are presently living with Alzheimer's disease - a figure projected to nearly double to 14 million by 2060. Consequently, the escalating prevalence of neurodegenerative conditions is propelling the expansion of the histone deacetylase (HDAC) inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp

Which Emerging Trends Are Transforming the Histone Deacetylase (HDAC) Inhibitors Market in 2025?
In their effort to improve efficacy and mitigate side effects, leading businesses in the histone deacetylase (HDAC) inhibitors market are concentrating on creating innovative strategies like HDAC inhibitors for cancer therapy. HDAC inhibitors fall under the category of medicinal compounds utilized in cancer treatment, working by repressing the activity of HDAC enzymes that typically take away acetyl groups from histone proteins. This inhibition results in the increased acetylation of histones, which modifies chromatin structure and impacts gene expression. For example, in the gone September 2023, Shuttle Pharmaceuticals Holdings Inc., an American company that proffers first-in-class therapies for cancer, was granted the New HDAC inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These ground-breaking inhibitors are designed to target specific HDAC enzymes involved in cancer's advancement, with the intention to interrupt abnormal gene expression patterns that aid tumor proliferation and metastasis. The patented compounds boast heightened potency and selectivity, reducing off-target impacts, and boosting safety profiles for patients in treatment.

What Are the Key Segments in the Histone Deacetylase (HDAC) Inhibitors Market?
The histone deacetylase (HDAC) inhibitors market covered in this report is segmented -

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
4) By Class IV HDACs: HDAC11

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp

Who Are the Key Players Shaping the Histone Deacetylase (HDAC) Inhibitors Market's Competitive Landscape?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

What Geographic Markets Are Powering Growth in the Histone Deacetylase (HDAC) Inhibitors Market?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18386

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.